Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 14/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.80 |
| ▸ | PGR | P06401 | 4/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.80 |
| ▸ | TNF | P01375 | 1/20 | 0.80 |
| ▸ | IL6 | P05231 | 1/20 | 0.80 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.80 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.80 |
| ▸ | AR | P10275 | 1/20 | 0.80 |
| ▸ | GLUL | P15104 | 1/20 | 0.80 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.80 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deprodone SCHEMBL11584541 | 1.00 | NR3C1 (0.80) | NR3C1HIF1APGRHSD17B10CYP3A4 | |
| Deprodone SCHEMBL31442907 | 1.00 | NR3C1 (0.80) | NR3C1HIF1APGRHSD17B10CYP3A4 | |
| Deprodone SCHEMBL12738232 | 1.00 | NR3C1 (0.80) | NR3C1HIF1APGRHSD17B10CYP3A4 | |
| Loteprednol SCHEMBL12396678 | 0.92 | NR3C1 (0.80) | NR3C1HIF1APGRHSD17B10CYP3A4 | |
| Loteprednol SCHEMBL5095876 | 0.92 | NR3C1 (0.80) | NR3C1HIF1APGRHSD17B10CYP3A4 | |
| Loteprednol SCHEMBL23974878 | 0.92 | NR3C1 (0.80) | NR3C1HIF1APGRHSD17B10CYP3A4 | |
| Loteprednol SCHEMBL1685771 | 0.92 | NR3C1 (0.80) | NR3C1HIF1APGRHSD17B10CYP3A4 | |
| Loteprednol SCHEMBL15803210 | 0.92 | NR3C1 (0.80) | NR3C1HIF1APGRHSD17B10CYP3A4 | |
| Loteprednol SCHEMBL12738241 | 0.92 | NR3C1 (0.80) | NR3C1HIF1APGRHSD17B10CYP3A4 | |
| Loteprednol SCHEMBL1626518 | 0.92 | NR3C1 (0.80) | NR3C1HIF1APGRHSD17B10CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 874 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12419619-B2 | Aspiration device | YALE UNIVERSITY (US) | 2025-09-23 | — | — | US | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| EP-4225267-A1 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | Chiesi Farmaceutici S.p.A. (IT) | 2023-08-16 | — | — | EP | claimed |
| US-20230218630-A1 | COMBINATION OF ALCAFTADINE AND A CORTICOSTEROID | ALKEM LABORATORIES LIMITED (IN) | 2023-07-13 | — | — | US | claimed |
| US-11648245-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2023-05-16 | — | — | US | claimed |
| EP-4164614-A1 | COMBINATION OF ALCAFTADINE AND A CORTICOSTEROID | Alkem Laboratories Limited (IN) | 2023-04-19 | — | — | EP | claimed |
| US-20220096498-A1 | INJECTABLE SUSTAINED-RELEASE FORMULATIONS FOR TREATMENT OF JOINT PAIN AND INFLAMMATION | FORDOZ PHARMA CORP. (US) | 2022-03-31 | — | — | US | claimed |
| US-20210401798-A1 | LIPOXIN A4 ANALOGS AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-12-30 | — | — | US | claimed |
| WO-2021255622-A1 | COMBINATION OF ALCAFTADINE AND A CORTICOSTEROID | ALKEM LABORATORIES LIMITED (IN) | 2021-12-23 | — | — | WO | claimed |
| US-20210369701-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. | 2021-12-02 | — | — | US | claimed |
| CN-1447804-A | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | ATHEROGENICS INC (US) | 2003-10-08 | — | — | CN | claimed |
| US-6608101-B1 | Inflammatory disorders; 3-(2,4-dimethoxy-5-(thien-2-yl)phenyl)-1-(4-carboxymethoxy-3,5 -dimethoxyphenyl)-2-propen-1-one; | ATHEROGENICS, INC. | 2003-08-19 | — | — | US | claimed |
| US-20030119786-A1 | Combinations for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2003-06-26 | — | — | US | claimed |
| WO-2003030823-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2003-04-17 | — | — | WO | claimed |
| US-6428804-B1 | INJECTABLE MICROCAPSULES CONTAINING BIODEGRADABLE, BIOCOMPAT-IBLE HIGH MOLECULAR WEIGHT POLYMER AND THERAPEUTIC DRUG SUS-PENDED IN HYALURONIC ACID AND/OR CHONDROITIN SULFATE MEDIUM; INHIBITS SIDE EFFECTS; LONG TERM EFFICACY | SSP CO., LTD. (JP) | 2002-08-06 | — | — | US | claimed |
| US-6197326-B1 | ADMINISTERING HYALURONIC ACID, CHONDROITIN SULFATE AND SALTS BY INJECTION FOR JOINT PAIN | SSP CO., LTD. (JP) | 2001-03-06 | — | — | US | claimed |
| CN-1215589-A | Intra-articular preparation for treatment of arthropathy | SSP CO LTD (JP) | 1999-05-05 | — | — | CN | claimed |
| EP-0911025-A1 | Intra-articular preparation for the treatment of arthropathy | SSP Co., Ltd. (JP) | 1999-04-28 | — | — | EP | claimed |
| EP-0473810-B1 | Water and deprodone proprionate -containing external preparations | SS PHARMACEUTICAL CO (JP) | 1996-05-29 | — | — | EP | claimed |
| EP-0473811-B1 | Ointment containing deprodone proprionate | SS PHARMACEUTICAL CO (JP) | 1995-05-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648245-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | NR3C1, GRIN3A, NR3C2 | NR3C1 1/4885HIF1A 4622/4885PGR 186/4885 |
| US-20210401798-A1 | LIPOXIN A4 ANALOGS AND USES THEREOF | LTA4H, ALOX15B, LTB4R | NR3C1 736/4885HIF1A 1354/4885PGR 3400/4885 |
| US-20210369701-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, GRIN3A, NR3C2 | NR3C1 1/4885HIF1A 4622/4885PGR 186/4885 |
| US-20030119786-A1 | Combinations for the treatment of immunoinflammatory disorders | IL5, TSLP, TPMT | NR3C1 32/4885HIF1A 1616/4885PGR 1880/4885 |
| US-20230218630-A1 | COMBINATION OF ALCAFTADINE AND A CORTICOSTEROID | CCL11, IL5, TSLP | NR3C1 9/4885HIF1A 4348/4885PGR 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.